

**TaiMed Biologics Inc.**  
**2023 Shareholders' Meeting Minutes**  
( translation )

Time: 9:30 a.m., May 11 (Thursday), 2023

Place: Training Center, MasterLink Securities Corporation

(11 F, No. 97, Duen Hua S. Rd., Sec 2, Taipei, Taiwan)

Total outstanding TMB shares: 252,668,000 shares

Total shares represented by shareholders present in person or by proxy:  
145,717,520 shares

Percentage of shares held by shareholders present in person or by proxy:  
57.67%

Directors present: James Chang, Chin-Ting, Chiu

Chairman: James Chang

Recorder: Jack Chen

**1. Chairman Address (omitted)**

**2. Report Items**

- ( 1 ) 2022 business report and the implementation report for the sound operating plan
- ( 2 ) Audit Committee's Review Report
- ( 3 ) Report on the amendment to the "Code of Practices for Sustainable Development."
- ( 4 ) Report on the amendment to "Regulations for Directors' and Independent Directors' Compensation."

Q: Please explain the research and development plan and the company's sales operation in detail.

A: In addition to the relevant content of the business report, both the chairman and the CEO are clear about the analysis of the Trogarzo sales status, the implementation progress of the company's various

R&D plans, the industry's competitive environment, the evaluation of future partnership, and other material issues concerned to shareholders.

### 3. Items for Acknowledgment

(1) Adoption of 2022 business report and financial statements

Voting Results:

Shares represented at the time of voting: 139,831,380

Voting Results*	% of the total represented shares present
Votes in favor: 132,825,723 votes	94.98%
Votes against: 125,206 votes	0.08%
Votes invalid: 66,000 votes	0.04%
Votes abstained: 6,814,451 votes	4.87%

\*including votes cast electronically (numbers in brackets)

RESOLVED that the 2022 business report and financial statements be accepted as summited.

(2) Adoption of the Proposal for 2022 Deficit Compensation

Voting Results:

Shares represented at the time of voting: 139,831,380

Voting Results*	% of the total represented shares present
Votes in favor: 132,730,021 votes	94.92%
Votes against: 131,398 votes	0.09%
Votes invalid: 126,000 votes	0.09%
Votes abstained: 6,843,961 votes	4.89%

\*including votes cast electronically (numbers in brackets)

RESOLVED that the above proposal be and at this moment was approved as proposed.

**4. Items for Discussions:**

( 1) On the lifting of non-competition restrictions for directors

Voting Results:

Shares represented at the time of voting: 139,831,380

Voting Results*		% of the total represented shares present
Votes in favor:	132,725,565 votes	94.91%
Votes against:	104,906 votes	0.07%
Votes invalid:	66,000 votes	0.04%
Votes abstained:	6,934,909 votes	4.95%

\*including votes cast electronically (numbers in brackets)

RESOLVED that the above proposal be and at this moment was approved as proposed.

**5. Temporary Motions: none**

**6. Adjournment**